Celltrion Pharm

(주)셀트리온제약 · KOSDAQ · 068760 · Industry: Manufacture of medicaments

Key metrics

Earnings

Revenue, Q3 2026₩161.9bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQ+5.6% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Revenue YoY+17.2% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income, Q3 2026₩23.9bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQ+23.8% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income YoY+48.4% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗

Share buybacks

Buyback decided, last 3 months₩0 As of Nov 19, 2026
Buyback decided, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 3 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 3 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Buyback decided, last 12 months₩0 As of Nov 19, 2026
Buyback decided, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 12 months₩0 As of Nov 19, 2026
Shares acquired, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 12 months₩14.0bn As of Feb 12, 2026 Source 1 ↗
Treasury shares cancelled (number), last 12 months149,993 shares As of Feb 12, 2026 Source 1 ↗
Treasury shares cancelled, last 12 months, % of shares0.3% As of Feb 12, 2026 Source 1 ↗, Source 2 ↗

Potential dilution

CB/BW/EB issued, last 12 months₩0 As of Nov 19, 2026
Rights offering new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Conversion price adjustments, last 12 months0 As of Nov 19, 2026

Supply contracts

Supply contracts, last 12 months₩0 As of Nov 19, 2026
Supply contracts vs prior-year revenue0.0% As of Nov 19, 2026
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months3 As of Nov 19, 2026
DART filings, previous 3 months6 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market buys, last 12 months (amount)₩0 As of Nov 19, 2026
Open-market sells, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market sells, last 12 months (amount)₩0 As of Nov 19, 2026
Net open-market buying, last 12 months (shares)0 shares As of Nov 19, 2026
Insiders who bought, last 12 months0 As of Nov 19, 2026

Insider transactions (last 12 months)

Open-market buys: 0 shares (₩0). Open-market sells: 0 shares (₩0). Net open-market buying: 0 shares. Insiders who bought: 0.

Trade dateInsider (role)TypeSharesPriceAmount
Mar 24, 2026Choi Seung-jae (Non-registered officer)Other+105 shares₩500₩52,500
Mar 24, 2026Lee Eon-hyeong (Non-registered officer)Other+191 shares₩500₩95,500
Mar 24, 2026Yang Ji-seok (Non-registered officer)Other+114 shares₩500₩57,000
Mar 24, 2026Choi Deok-gyu (Non-registered officer)Other+165 shares₩500₩82,500
Mar 24, 2026Yoo Yeong-ho (Registered director)Other+117 shares₩500₩58,500
Mar 24, 2026Kim Ju-beom (Non-registered officer)Other+45 shares₩500₩22,500
Mar 24, 2026Kim Seung-hwan (Non-registered officer)Other+8 shares₩500₩4,000
Mar 24, 2026Celltrion, Inc. (10%+ shareholder)Other+478,749 shares——
Feb 14, 2026Woo Yeong-je (Non-registered officer)Other (Retirement as officer)-6,066 shares——
Jan 29, 2026Kim Ju-beom (Non-registered officer)Other (Stock option exercise)+762 shares₩48,002₩37m

Annual financials

YearRevenueOperating income
2025₩536.4bn₩56.1bn
2024₩477.8bn₩37.2bn
2023₩388.8bn₩36.1bn

Filing timeline